

Mochida announces Termination of License Agreement with Merck & Co., Inc., Kenilworth, N.J., U.S.A.

Mochida Pharmaceutical Co., Ltd.

(Tokyo, May 15, 2015) Mochida Pharmaceutical Co., Ltd. announces the termination of the license agreement with Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), relating to a portfolio of drug candidates invented by Mochida for the potential treatment for type-2 diabetes. Under the agreement, Merck & Co., Inc. had been granted a worldwide exclusive license to develop, manufacture, use and sell the potential drug candidates and had been developing such drug candidates.

Upon termination of the agreement, Mochida gets back the exclusive right relating to such drug candidates. Hereafter, Mochida will consider developing these drug candidates, and engaging in licensing activities as well.

The termination of this agreement will have only minor impact on the business performance of Mochida for the near term.

For reference:

Previously-released notice on the above-mentioned Agreement licensing activities as well.

Press release titled “Mochida announces License Agreement with Merck” of December 13, 2011